The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience
Open accessAbstract
The acronym THERANOSTICS epitomizes the inseparability of diagnosis and therapy, the pillars of medicine and takes into account personalized management of disease for a specific patient. Molecular phenotypes of neoplasms can be determined by molecular imaging with specific probes using positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), or optical methods, so that the treatment is specifically targeted against the tumor and its environment. To meet these demands, we need to define the targets, ligands, coupling and labeling chemistry, the most appropriate radionuclides, biodistribution modifiers, and finally select the right patients for the personalized treatment. THERANOSTICS of neuroendocrine tumors (NETs) using Ga-68 labeled tracers for diagnostics with positron emission tomography/ computed tomography (PET/CT), and using Lu-177 or other metallic radionuclides for radionuclide therapy by applying the same peptide proves that personalized radionuclide therapy today is already a fact and not a fiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Hofmann, M., Maecke, H., Börner, A., Weckesser, E., Schöffski, P., Oei, M., Schumacher, J., Henze, M., Heppeler, A., Meyer, G., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100639 · Cited by 544
Buchmann, I., Henze, M., Engelbrecht, S., Eisenhut, M., Runz, A., Schäfer, M., Schilling, T., Haufe, S., Herrmann, T., & Haberkorn, U. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0450-1 · Cited by 506
Srirajaskanthan, R., Kayani, I., Quigley, A. M., Soh, J., Caplin, M. E., & Bomanji, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066134 · Cited by 310
Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073239 · Cited by 308
Self-citationKowalski, J. (2003) · Molecular Imaging & Biology · doi:10.1016/s1536-1632(03)00038-6 · Cited by 304
Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT
Prasad, V., Ambrosini, V., Hommann, M., Hoersch, D., Fanti, S., & Baum, R. P. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1205-y · Cited by 249
Self-citation(68)Ga-labeled peptides in tumor imaging.
Maëcke, H. R., Hofmann, M., & Haberkorn, U. (2005) · PubMed · Cited by 242
Kunikowska, J., Królicki, L., Hubalewska-Dydejczyk, A., Mikołajczak, R., Sowa-Staszczak, A., & Pawlak, D. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1833-x · Cited by 238
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
Ambrosini, V., Campana, D., Bodei, L., Nanni, C., Castellucci, P., Allegri, V., Montini, G. C., Tomassetti, P., Paganelli, G., & Fanti, S. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.071712 · Cited by 232
Wehrmann, C., Senftleben, S., Zachert, C., Müller, D., & Baum, R. P. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2006.325 · Cited by 177
Self-citationKaemmerer, D., Peter, L., Lupp, A., Schulz, S., Sänger, J., Prasad, V., Kulkarni, H., Haugvik, S., Hommann, M., & Baum, R. P. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1846-5 · Cited by 155
Self-citationMajkowska‐Pilip, A., & Bilewicz, A. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.11.003 · Cited by 140
Szanda, I., Mackewn, J. E., Patay, G., Major, P., Sunassee, K., Mullen, G. E. D., Nemeth, G., Hämisch, Y., Blower, P. J., & Marsden, P. K. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088260 · Cited by 132
Koukouraki, S. I., Strauss, L. G., Georgoulias, V., Schuhmacher, J., Haberkorn, U., Karkavitsas, N. S., & Dimitrakopoulou‐Strauss, A. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-0006-1 · Cited by 127
Boy, C., Heusner, T. A., Poeppel, T. D., Redmann-Bischofs, A., Unger, N., Jentzen, W., Brandau, W., Mann, K., Antoch, G., Bockisch, A., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1760-x · Cited by 125
Prasad, V., & Baum, R. P. (2010) · PubMed · Cited by 123
Self-citationSowa‐Staszczak, A., Pach, D., Chrzan, R. M., Trofimiuk, M., Stefańska, A., Tomaszuk, M., Kołodziej, M., Mikołajczak, R., Pawlak, D., & Hubalewska–Dydejczyk, A. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1835-8 · Cited by 110
68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours
Naji, M., Zhao, C., Welsh, S. J., Meades, R., Win, Z., Ferrarese, A., Tan, T., Rubello, D., & AL-NAHHAS, A. M. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0396-8 · Cited by 95
Neoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumor
Kaemmerer, D., Prasad, V., Daffner, W., Hörsch, D., Klöppel, G., Hommann, M., & Baum, R. P. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5867 · Cited by 85
Self-citationReceptor PET/CT Imaging of Neuroendocrine Tumors
Baum, R. P., Prasad, V., Hommann, M., & Hörsch, D. (2008) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-31203-1_18 · Cited by 66
Self-citationKrenning, E. P., Kwekkeboom, D. J., de Jong, M., Visser, T. J., Reubi, J. C., Bakker, W. H., Kooij, P. P., & Lamberts, S. W. (1994) · PubMed · Cited by 46
Somatostatin and the concept of peptide receptor scintigraphy in oncology.
Lamberts, S. W. J., Jc, R., & Krenning, E. P. (1994) · PubMed · Cited by 31
Cited by
Matching chelators to radiometals for radiopharmaceuticals
Price, E. W., & Orvig, C. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60304k · Cited by 1,018
Cherry, S. R., Jones, T., Karp, J. S., Qi, J., Moses, W. W., & Badawi, R. D. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.184028 · Cited by 763
Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Mueller, D., Klette, I., & Wester, H.-J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 525
Self-citationProspective of 68Ga-Radiopharmaceutical Development
Velikyan, I. (2014) · Theranostics · doi:10.7150/thno.7447 · Cited by 336
Nanobody: The “Magic Bullet” for Molecular Imaging?
Chakravarty, R., Goel, S., & Cai, W. (2014) · Theranostics · doi:10.7150/thno.8006 · Cited by 288
Metadata
- Authors
- Baum, R. P., & Kulkarni, H. R.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2012
- Volume
- 2
- Issue
- 5
- Pages
- 437-447
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2122334532
- Cited by
- 283
- References
- 24
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.